Magee Thomson Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Magee Thomson Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-177,500	Closed	-$13.6M	–	109
2015 Q4	$13.6M	Buy	177,500 +42,200	+31%	+$2.39M	3.75%	11
2015 Q3	$5.56M	Buy	135,300 +11,760	+10%	+$720K	1.71%	29
2015 Q2	$8.74M	Buy	123,540 +4,340	+4%	+$342K	2.53%	27
2015 Q1	$10.6M	Sell	119,200 -5,784	-5%	-$587K	2.56%	24
2014 Q4	$11.1M	Sell	124,984 -1,038	-0.8%	-$98.2K	2.75%	22
2014 Q3	$12.2M	Buy	126,022 +122,130	+3,138%	+$11.9M	3.01%	17
2014 Q2	$357K	Hold	3,892	–	–	0.09%	35
2014 Q1	$272K	Hold	3,892	–	–	0.06%	47
2013 Q4	$224K	Hold	3,892	–	–	0.05%	68
2013 Q3	$188K	Buy	3,892 +1,876	+93%	+$68.4K	0.04%	68
2013 Q2	$58K	Buy	+2,016	New	+$58.3K	0.01%	86

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Magee Thomson Investment Partners's PCRX Position: Q1 2016 in Review

Magee Thomson Investment Partners sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 177,500 shares — an estimated $13.6M sold.

Magee Thomson Investment Partners first reported a position in PCRX in Q2 2013 and held it in 11 quarters. The position peaked at $13.6M in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

Magee Thomson Investment Partners reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
Magee Thomson Investment Partners sold 177,500 Pacira BioSciences shares in Q1 2016, an estimated $13.6M.
Magee Thomson Investment Partners first reported a position in Pacira BioSciences in Q2 2013 and held it in 11 quarters.
Magee Thomson Investment Partners's Pacira BioSciences position peaked at $13.6M in Q4 2015.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2016, filed 20 Apr 2016.